摘要
目的观察吉西他滨(GEM)联合奥沙利铂(L-OHP)治疗复治性中晚期食管贲门癌的疗效及不良反应。方法30例复治性中晚期食管贲门癌患者(食管癌16例,贲门癌14例)应用GP方案化疗(GP方案GEM1.0g/m2,静脉滴入,d1、d8;L-OHP65mg/m2,静脉滴入,d1、d8;21d为1个周期)。2个周期后评价疗效及不良反应。结果30例患者均可评价疗效,共完成115个周期化疗,平均3.83个周期;其中CR1例(3.3%),PR8例(26.7%),NC9例(30%),PD12例(40%),客观有效率(CR+PR)为30%;中位TTP4.8个月;中位生存期6.8个月;1年生存率为10%(3/30)。主要不良反应为骨髓抑制和神经毒性。结论GEM+L-OHP方案治疗复治性中晚期食管贲门癌近期疗效肯定,不良反应轻微,患者耐受性好。
OBJECTIVE：To evaluate the effect and toxicity of gemcitabine plus oxaliplatin in the treatment of advanced esophageal cancer and cardiac cancer. METHODS： Thirty patients including 16 advanced esophageal cancer patients and 14 advanced cardiac cancer patients were treated with GEM ＋ L-OHP regimen. Twenty-one days was as one cycle and the patients underwent, 3.83 cycles averagely. RESULTS： The overall response rate was 30% with complete response 1 （3.3%）, partial response 8（26.7%）, stable disease 9（30%） and progress disease 12 （40%）. Median TTP was 4.8 months. Median overall survival was 6.8 months, and 1-year survival rate was 10%. The main side effect included nausea, vomiting, neurotoxicity and bone suppression. CONCLUSION： GEM＋ L-OHP regimen is an effective regimen in the treatment of patients with advanced esophageal cancer and cardiac cancer with tolerable side effect.
出处
《中华肿瘤防治杂志》
CAS
2006年第22期1747-1748,共2页
Chinese Journal of Cancer Prevention and Treatment
关键词
食管肿瘤/药物疗法
胃肿瘤/药物疗法
脱氧胞苷/投药和剂量
有机铂化合物/投药和剂量
贲门
esophageal neoplasms/drug therapy, stomach neoplasms/drug thempy,deoxycytidine/administration ＆ dosage,organoplatinum compounds/administration ＆ dosage
cardia
